Get the Stockscreener App
27.99
4.11%
-1.20
After Hours:
27.99
Tyra Biosciences Inc stock is traded at $27.99, with a volume of 481.52K.
It is down -4.11% in the last 24 hours and down -2.85% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$29.19
Open:
$29.41
24h Volume:
481.52K
Relative Volume:
0.78
Market Cap:
$1.49B
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-17.39
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
-9.71%
1M Performance:
-2.85%
6M Performance:
+160.37%
1Y Performance:
+128.49%
1-Day Range:
$27.82
$30.26
1-Week Range:
$24.88
$33.99
52-Week Range:
$6.42
$33.99
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
27.99 | 1.56B | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Price-Driven Insight from (TYRA) for Rule-Based Strategy - Stock Traders Daily
RSI Check: Is Tyra Biosciences Inc a turnaround storyWeekly Trading Summary & Intraday High Probability Alerts - baoquankhu1.vn
Tyra Biosciences price target raised to $53 from $37 at Wedbush - Yahoo Finance
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
DKAs Burden The Clinical and Economic Impact - William Blair
Is Tyra Biosciences Inc.’s ROE strong enoughMarket Movement Recap & High Return Trade Guides - mfd.ru
Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch - TipRanks
Wedbush Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $53.00 - MarketBeat
Growth Stocks To Follow Today – February 11th - Defense World
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month HighTime to Buy? - MarketBeat
Wedbush Raises Price Target on Tyra Bioscience to $53 From $37, Keeps Outperform Rating - marketscreener.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can Tyra Biosciences Inc. continue delivering strong returnsTrade Analysis Report & Weekly Stock Performance Updates - mfd.ru
William Blair initiates coverage on Tyra Biosciences stock with Outperform rating - Investing.com Canada
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $37 - 富途牛牛
William Blair Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $59.62 - 富途牛牛
Tyra Biosciences stock hits 52-week high, reaching $31.0 By Investing.com - Investing.com South Africa
Tyra Biosciences stock hits 52-week high, reaching $31.0 - Investing.com
Nasdaq Moves: Is Crown Holdings Inc a speculative investmentTrade Ideas & Low Volatility Stock Suggestions - baoquankhu1.vn
AlphaQuest LLC Has $421,000 Holdings in Tyra Biosciences, Inc. $TYRA - MarketBeat
June Brings on Some Huge Insider Buying - AOL.com
(TYRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Tyra Biosciences Inc. stock is seen as undervalued2025 Pullback Review & AI Optimized Trading Strategy Guides - mfd.ru
Tyra Biosciences Advances BEACH301 Dose Escalation - TipRanks
Tyra Biosciences (TYRA) Price Target Increased by 24.36% to 42.58 - Nasdaq
Resistance Check: Is Tyra Biosciences Inc a strong candidate for buy and holdJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Jefferies Financial Group Forecasts Strong Price Appreciation for Tyra Biosciences (NASDAQ:TYRA) Stock - MarketBeat
Top Growth Stocks To Watch Now – January 31st - Defense World
Big Picture: What are the risks of holding Tyra Biosciences IncMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Promising 17% Upside Potential in Precision Medicine - DirectorsTalk Interviews
Forecast Cut: Can Tyra Biosciences Inc continue delivering strong returnsWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $59 - 富途牛牛
Tyra Biosciences stock price target raised to $55 from $35 at Raymond James - Investing.com Canada
Barclays Initiates Coverage of Tyra Biosciences (TYRA) with Overweight Recommendation - Nasdaq
Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month HighShould You Buy? - MarketBeat
Tyra Biosciences stock hits all-time high of 31.58 USD - Investing.com
Tyra Biosciences stock hits all-time high of 31.58 USD By Investing.com - Investing.com UK
Technical Analysis: Can Tyra Biosciences Inc continue delivering strong returns2025 Buyback Activity & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Assessing Tyra Biosciences (TYRA) Valuation After Piper Sandler Reaffirms Overweight On Dabogratinib Prospects - Sahm
(TYRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Promising Growth Stocks To Watch NowJanuary 25th - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.1%What's Next? - MarketBeat
Tyra Biosciences (TYRA) Stock Report: Biotechnology Innovator with an 8.61% Upside Potential - DirectorsTalk Interviews
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Piper Sandler raises Tyra Biosciences stock price target to $42 on growth outlook - Investing.com Canada
Tyra Biosciences stock hits 52-week high at 30.85 USD By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Tyra Biosciences stock hits 52-week high at 30.85 USD - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):